These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

145 related articles for article (PubMed ID: 38962049)

  • 1. Remarkable response to capmatinib in a patient with intrahepatic cholangiocarcinoma harboring
    Ueta A; Yamada A; Yoshioka M; Kanai M; Muto M; Okita N
    Int Cancer Conf J; 2024 Jul; 13(3):199-203. PubMed ID: 38962049
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Response to Capmatinib in a MET Fusion-positive Cholangiocarcinoma.
    Turpin A; Descarpentries C; Grégoire V; Farchi O; Cortot AB; Jamme P
    Oncologist; 2023 Jan; 28(1):80-83. PubMed ID: 36434677
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Partial treatment response to capmatinib in
    Lefler DS; Tierno MB; Bashir B
    Cancer Biol Ther; 2022 Dec; 23(1):112-116. PubMed ID: 35129063
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Response to capmatinib in a patient with neuroendocrine carcinoma of the gallbladder origin harboring
    Yamamura S; Kanai M; Takeuchi Y; Okita N; Kondo T; Yoshioka M; Matsubara J; Matsumoto S; Muto M
    Int Cancer Conf J; 2024 Apr; 13(2):83-87. PubMed ID: 38524646
    [TBL] [Abstract][Full Text] [Related]  

  • 5. The Development and Role of Capmatinib in the Treatment of MET-Dysregulated Non-Small Cell Lung Cancer-A Narrative Review.
    Hsu R; Benjamin DJ; Nagasaka M
    Cancers (Basel); 2023 Jul; 15(14):. PubMed ID: 37509224
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Case Report: Persistent response to combination therapy of pemigatinib, chemotherapy, and immune checkpoint inhibitor in a patient with advanced intrahepatic cholangiocarcinoma.
    Zhang Z; Wang G; Du L; Zhao J; Pan L; Zhang G; Wang F; Liu R
    Front Immunol; 2023; 14():1124482. PubMed ID: 37292215
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Complete response to capmatinib in a patient with metastatic lung adenocarcinoma harboring CD47-MET fusion: a case report.
    Alves de Souza G; Dornellas DMS; Campregher PV; Teixeira CHA; Schvartsman G
    Oncologist; 2024 Jun; ():. PubMed ID: 38832711
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Capmatinib for patients with non-small cell lung cancer with MET exon 14 skipping mutations: A review of preclinical and clinical studies.
    Wu YL; Smit EF; Bauer TM
    Cancer Treat Rev; 2021 Apr; 95():102173. PubMed ID: 33740553
    [TBL] [Abstract][Full Text] [Related]  

  • 9. The Efficacy and Safety of Treating Acquired MET Resistance Through Combinations of Parent and MET Tyrosine Kinase Inhibitors in Patients With Metastatic Oncogene-Driven NSCLC.
    Patil T; Staley A; Nie Y; Sakamoto M; Stalker M; Jurica JM; Koehler K; Cass A; Kuykendall H; Schmitt E; Filar E; Reventaite E; Davies KD; Nijmeh H; Haag M; Yoder BA; Bunn PA; Schenk EL; Aisner DL; Iams WT; Marmarelis ME; Camidge DR
    JTO Clin Res Rep; 2024 Feb; 5(2):100637. PubMed ID: 38361741
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Profile of Capmatinib for the Treatment of Metastatic Non-Small Cell Lung Cancer (NSCLC): Patient Selection and Perspectives.
    Fraser M; Seetharamu N; Diamond M; Lee CS
    Cancer Manag Res; 2023; 15():1233-1243. PubMed ID: 37941971
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Capmatinib in MET Exon 14 Skipping Mutation-Positive Lung Adenocarcinoma with Extensive Central Nervous System Metastasis.
    Kim TW; Lee KM; Lee SH
    Onco Targets Ther; 2022; 15():941-946. PubMed ID: 36072511
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Phase Ib/II Study of Capmatinib (INC280) Plus Gefitinib After Failure of Epidermal Growth Factor Receptor (EGFR) Inhibitor Therapy in Patients With EGFR-Mutated, MET Factor-Dysregulated Non-Small-Cell Lung Cancer.
    Wu YL; Zhang L; Kim DW; Liu X; Lee DH; Yang JC; Ahn MJ; Vansteenkiste JF; Su WC; Felip E; Chia V; Glaser S; Pultar P; Zhao S; Peng B; Akimov M; Tan DSW
    J Clin Oncol; 2018 Nov; 36(31):3101-3109. PubMed ID: 30156984
    [TBL] [Abstract][Full Text] [Related]  

  • 13. FGFR2 fusion proteins drive oncogenic transformation of mouse liver organoids towards cholangiocarcinoma.
    Cristinziano G; Porru M; Lamberti D; Buglioni S; Rollo F; Amoreo CA; Manni I; Giannarelli D; Cristofoletti C; Russo G; Borad MJ; Grazi GL; Diodoro MG; Giordano S; Sacconi A; Forcato M; Anastasi S; Leonetti C; Segatto O
    J Hepatol; 2021 Aug; 75(2):351-362. PubMed ID: 33741397
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Prolonged survival and response to tepotinib in a non-small-cell lung cancer patient with brain metastases harboring
    Roth KG; Mambetsariev I; Salgia R
    Cold Spring Harb Mol Case Stud; 2020 Dec; 6(6):. PubMed ID: 33335011
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Effectiveness of standard treatments in non-small-cell lung cancer with METexon14 skipping mutation: a real-world study.
    Furqan M; Karanth S; Goyal RK; Cai B; Rombi J; Davis KL; Caro N; Saliba T
    Future Oncol; 2024 Apr; ():1-11. PubMed ID: 38629593
    [No Abstract]   [Full Text] [Related]  

  • 16. Durable Response of Dabrafenib, Trametinib, and Capmatinib in an NSCLC Patient With Co-Existing BRAF-KIAA1549 Fusion and MET Amplification: A Case Report.
    Chou YT; Lin CC; Lee CT; Pavlick DC; Su PL
    Front Oncol; 2022; 12():838798. PubMed ID: 35372088
    [No Abstract]   [Full Text] [Related]  

  • 17. Pharmacokinetics and safety of capmatinib with food in patients with MET-dysregulated advanced solid tumors.
    Moreno V; Greil R; Yachnin J; Majem M; Wermke M; Arkenau HT; Basque JR; Nidamarthy PK; Kapoor S; Cui X; Giovannini M
    Clin Ther; 2021 Jun; 43(6):1092-1111. PubMed ID: 34053700
    [TBL] [Abstract][Full Text] [Related]  

  • 18. A Phase 2 Study of Capmatinib in Patients With MET-Altered Lung Cancer Previously Treated With a MET Inhibitor.
    Dagogo-Jack I; Moonsamy P; Gainor JF; Lennerz JK; Piotrowska Z; Lin JJ; Lennes IT; Sequist LV; Shaw AT; Goodwin K; Stevens SE; Do A; Digumarthy SR; Price K; Muzikansky A; Hata AN; Heist RS
    J Thorac Oncol; 2021 May; 16(5):850-859. PubMed ID: 33545388
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Tepotinib Efficacy in a Patient with Non-Small Cell Lung Cancer with Brain Metastasis Harboring an HLA-DRB1-MET Gene Fusion.
    Blanc-Durand F; Alameddine R; Iafrate AJ; Tran-Thanh D; Lo YC; Blais N; Routy B; Tehfé M; Leduc C; Romeo P; Stephenson P; Florescu M
    Oncologist; 2020 Nov; 25(11):916-920. PubMed ID: 32716573
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Capmatinib is an effective treatment for MET-fusion driven pediatric high-grade glioma and synergizes with radiotherapy.
    Zuckermann M; He C; Andrews J; Bagchi A; Sloan-Henry R; Bianski B; Xie J; Wang Y; Twarog N; Onar-Thomas A; Ernst KJ; Yang L; Li Y; Zhu X; Ocasio JK; Budd KM; Dalton J; Li X; Chepyala D; Zhang J; Xu K; Hover L; Roach JT; Chan KC; Hofmann N; McKinnon PJ; Pfister SM; Shelat AA; Rankovic Z; Freeman BB; Chiang J; Jones DTW; Tinkle CL; Baker SJ
    Mol Cancer; 2024 Jun; 23(1):123. PubMed ID: 38849845
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 8.